GeneDx Statistics
Share Statistics
GeneDx has 28.53M
shares outstanding. The number of shares has increased by 7.33%
in one year.
| Shares Outstanding | 28.53M |
| Shares Change (YoY) | 7.33% |
| Shares Change (QoQ) | 2.17% |
| Owned by Institutions (%) | 86.83% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 455 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 3.57M, so 12.52% of the outstanding
shares have been sold short.
| Short Interest | 3.57M |
| Short % of Shares Out | 12.52% |
| Short % of Float | 31.07% |
| Short Ratio (days to cover) | 2.25 |
Valuation Ratios
The PE ratio is -39.53 and the forward
PE ratio is 33.
GeneDx's PEG ratio is
0.54.
| PE Ratio | -39.53 |
| Forward PE | 33 |
| PS Ratio | 6.77 |
| Forward PS | 3 |
| PB Ratio | 8.43 |
| P/FCF Ratio | -60.81 |
| PEG Ratio | 0.54 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for GeneDx.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61,
with a Debt / Equity ratio of 0.47.
| Current Ratio | 3.61 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | -5 |
| Debt / FCF | -3.42 |
| Interest Coverage | 7.66 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $305,450 |
| Profits Per Employee | $-52,286 |
| Employee Count | 1,000 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 10.43 |
Taxes
| Income Tax | -343K |
| Effective Tax Rate | 0.65% |
Stock Price Statistics
The stock price has increased by 247.38% in the
last 52 weeks. The beta is 2.04, so GeneDx's
price volatility has been higher than the market average.
| Beta | 2.04 |
| 52-Week Price Change | 247.38% |
| 50-Day Moving Average | 84.9 |
| 200-Day Moving Average | 70.54 |
| Relative Strength Index (RSI) | 47.48 |
| Average Volume (20 Days) | 1,142,949 |
Income Statement
In the last 12 months, GeneDx had revenue of 305.45M
and earned -52.29M
in profits. Earnings per share was -1.94.
| Revenue | 305.45M |
| Gross Profit | 194.4M |
| Operating Income | -23.21M |
| Net Income | -52.29M |
| EBITDA | -23.21M |
| EBIT | -55.66M |
| Earnings Per Share (EPS) | -1.94 |
Full Income StatementBalance Sheet
The company has 85.21M in cash and 116.17M in
debt, giving a net cash position of -30.96M.
| Cash & Cash Equivalents | 85.21M |
| Total Debt | 116.17M |
| Net Cash | -30.96M |
| Retained Earnings | -1.35B |
| Total Assets | 446.43M |
| Working Capital | 156.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -28.5M
and capital expenditures -5.49M, giving a free cash flow of -33.99M.
| Operating Cash Flow | -28.5M |
| Capital Expenditures | -5.49M |
| Free Cash Flow | -33.99M |
| FCF Per Share | -1.26 |
Full Cash Flow StatementMargins
Gross margin is 63.64%, with operating and profit margins of -7.6% and -17.12%.
| Gross Margin | 63.64% |
| Operating Margin | -7.6% |
| Pretax Margin | -17.23% |
| Profit Margin | -17.12% |
| EBITDA Margin | -7.6% |
| EBIT Margin | -7.6% |
| FCF Margin | -11.13% |
